All NewsBio/Pharma News
All PublicationsPharmTechPharmTech Europe
MarketplaceICH Q9 Revision: A Comprehensive Resource on Quality Risk ManagementPeer-Reviewed ResearchPharmTech ProductsPharma InsightsSponsored PodcastsSponsored VideosSponsored eBooksWhitepapers
Webcasts
All VideosAsk the ExpertBehind The HeadlinesBuy, Sell, HoldDrug Digest VideosDrug Solutions PodcastPeer ExchangeSexy ScienceTech Talk
Conference CoverageConference ListingEvents
Subscribe
AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality Systems
Spotlight -
  • Analytics
  • Dosage Forms
  • Drug Development
  • Manufacturing
  • Outsourcing
  • Quality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Webcasts
    • Subscribe
Advertisement

Court Rules No Link Between MMR Vaccine and Autism

February 19, 2009
By Pharmaceutical Technology Editors
News
Article

ePT--the Electronic Newsletter of Pharmaceutical Technology

After two years of hearings, more than 5000 pages of expert testimonies, and 939 medical articles, a special federal court ruled that there was little, if any, evidence to support the claim that substances in the measles, mumps, and rubella vaccine (including the use of thimerosal) had led to the autism of three children.

Washington, DC (Feb. 12)-After two years of hearings, more than 5000 pages of expert testimonies, and 939 medical articles, a special federal court ruled that there was little, if any, evidence to support the claim that substances in the measles, mumps, and rubella vaccine (including the use of thimerosal) had led to autism of three children. Three special masters presiding in the US Court of Federal Claims made the landmark decisions in cases against the US Secretary of Health and Human Services in which the families sought compensation through the government’s Vaccine Injury Compensation Program.

More than 5500 claims have been made regarding a possible link between the MMR vaccine, especially in cases where thimerisol was used, and autism. According to the Office of Special Masters, the autism proceedings involved designating three test cases to be considered for each of three theories of “general causation.” One of these theories was dropped, so that during the hearings, the test cases were investigated against the other two; namely, the theory that MMR vaccines and thimerosal-containing vaccines can combine to cause autism and the theory that thimerosal-containing vaccines can cause autism.

The National Vaccine Injury Compensation Program (VICP) is a federal no-fault program enacted in 1986 and mandates that vaccine-injury claims be considered first under VICP. The statute was intended to reduce lawsuits against physicians and manufacturers, while providing those claiming vaccine injuries a reduced burden of proof. Claimants under the VICP need not prove negligence, failure to warn, or other tort causes of action; they must only prove that a covered vaccine caused injury.

The uncertainty regarding the safety of MMR vaccines has led to an increasing number of parents chosing not to have their child vaccinated. Some medical experts claim these decisions were a major factor leading to an increasing occurrence of measles in children, to the point that the Center for Disease Control and Prevention reported that in 2008 measles had reached the highest levels in more than a decade.

Regarding the special court decision, Leonard Rappaport, MD, MS, chief of the Division of Developmental Medince at Children’s Hospital Boston, said, “Hopefully this decision will put an end to this sad chapter in the search for the cause and treatment of autism spectrum disorders.”

Recent Videos
Drug Digest: Patient Preference Drives Solid Dosage Trends
Behind the Headlines, Episode 17
Related Content

3d rendering of Human cell or Embryonic stem cell microscope background. | Image Credit: © Anusorn - stock.adobe.com

Ushering in Industry 4.0 with the IDMO Model to Solve the CGT Manufacturing Bottleneck

John Tomtishen
May 28th 2025
Article

Global scale-up requires developing replicable processes that work the same no matter where they are performed. This can be accomplished with smart factories that utilize fully automated manufacturing platforms.


Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
June 25th 2024
Podcast

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.


An antiviral used to treat hepatitis B and C | Image Credit © luchschenF

pharma& Secures MHRA Approval for Pegasys API Production at Loba Biotech

Christopher Cole
May 28th 2025
Article

MHRA approves Loba Biotech to manufacture Pegasys API, enabling pharma& to strengthen UK supply and ensure continued access for eligible patients.


Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Felicity Thomas
May 28th 2024
Podcast

In this episode, Alexander Natz from EUCOPE chats about the European Health Data Space.


Sanofi logo at one of skyscraper. Sanofi is a French biopharma company | Image Credit: © Robert - stock.adobe.com

Sanofi to Acquire Vigil Neuroscience to Expand Neurodegenerative Disease Pipeline

Christopher Cole
May 23rd 2025
Article

Sanofi is acquiring Vigil Neuroscience, a biotech firm focused on novel neurodegenerative disease therapies, to boost its early-stage neurology pipeline.


Data technology background. Abstract background. Connecting dots and lines on dark background. 3D rendering. 4k. | Image Credit: © Dmitry

Emerson Unveils AI Platform for Mission-Critical Industrial Applications

Christopher Cole
May 22nd 2025
Article

Emerson’s purpose-built industrial AI solutions are meant to enhance accessibility and reliability, enabling manufacturers to maximize efficiency and performance from automation systems.

Related Content

3d rendering of Human cell or Embryonic stem cell microscope background. | Image Credit: © Anusorn - stock.adobe.com

Ushering in Industry 4.0 with the IDMO Model to Solve the CGT Manufacturing Bottleneck

John Tomtishen
May 28th 2025
Article

Global scale-up requires developing replicable processes that work the same no matter where they are performed. This can be accomplished with smart factories that utilize fully automated manufacturing platforms.


Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
June 25th 2024
Podcast

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.


An antiviral used to treat hepatitis B and C | Image Credit © luchschenF

pharma& Secures MHRA Approval for Pegasys API Production at Loba Biotech

Christopher Cole
May 28th 2025
Article

MHRA approves Loba Biotech to manufacture Pegasys API, enabling pharma& to strengthen UK supply and ensure continued access for eligible patients.


Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Felicity Thomas
May 28th 2024
Podcast

In this episode, Alexander Natz from EUCOPE chats about the European Health Data Space.


Sanofi logo at one of skyscraper. Sanofi is a French biopharma company | Image Credit: © Robert - stock.adobe.com

Sanofi to Acquire Vigil Neuroscience to Expand Neurodegenerative Disease Pipeline

Christopher Cole
May 23rd 2025
Article

Sanofi is acquiring Vigil Neuroscience, a biotech firm focused on novel neurodegenerative disease therapies, to boost its early-stage neurology pipeline.


Data technology background. Abstract background. Connecting dots and lines on dark background. 3D rendering. 4k. | Image Credit: © Dmitry

Emerson Unveils AI Platform for Mission-Critical Industrial Applications

Christopher Cole
May 22nd 2025
Article

Emerson’s purpose-built industrial AI solutions are meant to enhance accessibility and reliability, enabling manufacturers to maximize efficiency and performance from automation systems.

About Us
Advertise
Contact Us
Editorial Info
Editorial Advisory Board
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.